ClinicalTrials.gg
RecruitingNCT07541079Updated Nov 12, 2026

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

A Phase 3 interventional study of Giredestrant in Early Breast Cancer, sponsored by Genentech, Inc.. Recruiting at 13 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 12, 202611 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Planned enrollment
9th of 16
300 · median 302
Started
2026
with 1 other
Phase 3
7 of 16
2 open now
Primary completion
2032-06
later than 11 of 11 live
Registered
15th of 16
by date
Lead sponsor
4 of 16
Genentech, Inc.

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 15th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance. Giredestrant will be administered as adjuvant endocrine therapy for participants with low-, medium-, and high-risk, Stage I-III, histologically confirmed, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (eBC), as defined by the investigator. Participants will enroll if considered to be intolerant to a prior adjuvant AI therapy.

03

Conditions studied

  • Early Breast Cancer

Browse trials for

Keywords

  • Estrogen receptor positive
  • ER+
  • Human epidermal growth factor receptor 2 negative
  • HER2-
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Considered appropriate for treatment with endocrine therapy (ET)
  • confirmed diagnosis of ER+/-, Stage I-III (low-/medium-/high-risk) early breast cancer (eBC)
  • Documented ER+ tumor according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP), defined as ≥1% of tumor cells stained positive
  • Documented HER2- tumor according to ASCO/CAP
  • females at the time of signing the Form
  • Documented use of a prior adjuvant aromatase inhibitor (AI) (i.e., anastrozole, exemestane, or letrozole) for a total of ≥6 months
  • Documented use of an adjuvant AI (i.e., anastrozole, exemestane, or letrozole) for the consecutive ≥3 months immediately prior to consent
  • Participant and investigator agree that current symptoms on AI are intolerable and warrant a switch in therapy to attempt sustained treatment
  • Documented Grade 2 or 3 adverse events, per v6.0, determined by the investigator to be associated with AI therapy's intolerance
  • Participant and investigator planning the first switch from an AI
  • Has completed the following: (neo) chemotherapy (if administered), definitive surgery of primary breast tumor(s) and/or axillary lymph nodes dissection (ALND) and/or sentinel lymph node (SLNB) and/or radiotherapy
  • Performance (ECOG) Performance Status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Participation within 6 months before enrollment in any other clinical study involving an treatment including anti-cancer agents
  • Diagnosis of rheumatoid arthritis, psoriatic arthritis, or other inflammatory connective tissue disease
  • Any prior fulvestrant or any oral selective estrogen receptor degraders (SERDs)
  • Have active cardiac disease or history of cardiac dysfunction
  • Have liver disease consistent with Class B or C, including active hepatitis (e.g., virus [HBV] or virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis
  • Treatment with strong inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Have had any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Giredestrant

    Drug: Giredestrant

Interventions

  • Participants will receive giredestrant at a dose of 30 mg orally once daily on Days 1-28 of each 28-day cycle for up to 4.5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. Incidence of Participants Who Have Discontinued Giredestrant for Any Reason at 12 Months

    Time frame: At 12 months

  2. Incidence and Severity of Adverse Events, with Severity Determined According to the National Cancer Institute Common Terminology Criteria of Adverse Events, version 6.0 (NCI CTCAE v6.0)

    Time frame: From baseline until 28 days after the final dose of study drug (up to 4 years, 7 months)

Secondary outcomes

  1. Percentage of Participants Achieving an Improvement in Individual Endocrine Therapy-specific Symptoms at 6 and 12 Months, Using the FACT-ES Questionnaire

    An improvement in individual endocrine therapy-specific symptoms (joint pain, hot flashes, vaginal dryness, and sexual dysfunction) is defined as ≥1-point/shift increase from baseline in the respective Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire items.

    Time frame: Baseline, 6 and 12 months

  2. Percentage of Participants Categorized as Improved, Stable, or Worsening in Endocrine Therapy-specific Symptom Burden at 6 and 12 Months, Using the FACT-ES Questionnaire

    Categories are defined by a change from baseline in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire Additional Concerns subscale score using a minimal important difference (MID) threshold of ±3 points.

    Time frame: Baseline, 6 and 12 months

  3. Percentage of Participants Categorized as Improved, Stable, or Worsened in Pain-related Burden at 6 and 12 Months, Using the BPI-SF Questionnaire

    Categories are defined by a change from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Pain Severity composite score (minimal important difference \[MID\] of ±2 points) and the BPI-SF Pain Interference composite score (MID of ±1 point).

    Time frame: Baseline, 6 and 12 months

  4. Percentage of Participants Achieving an Improvement in Global Treatment Bother at 6 and 12 Months, Using the FACT-ES Questionnaire's GP5 Item

    An improvement is defined as a ≥1-point increase from baseline in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) GP5 item ('I am bothered by side-effects of treatment').

    Time frame: Baseline, 6 and 12 months

  5. Percentage of Participants Categorized as Improved, Stable, or Worsened in Domain-specific Physical Well-Being at 6 and 12 Months, Using the FACT-ES Questionnaire

    Categories are defined by a change from baseline in the respective Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Physical Well-Being subscale scores using a minimal important difference (MID) threshold of ±2 points.

    Time frame: Baseline, 6 and 12 months

  6. Percentage of Participants Categorized as Improved, Stable, or Worsened in Domain-specific Functional Well-Being at 6 and 12 Months, Using the FACT-ES Questionnaire

    Categories are defined by a change from baseline in the respective Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Functional Well-Being subscale scores using a minimal important difference (MID) threshold of ±2 points.

    Time frame: Baseline, 6 and 12 months

  7. Percentage of Participants Categorized as Improved, Stable, or Worsened in Global Health-Related Quality of Life (HRQoL) at 6 and 12 Months, Using the FACT-ES Questionnaire

    Categories are defined by a change from baseline in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Total Score using a minimal important difference (MID) threshold of ±7 points.

    Time frame: Baseline, 6 and 12 months

07

Study locations

13 of 13 sites recruiting
  • Clearview Cancer Institute - Huntsville
    Huntsville, Alabama 35805-2606, United States
    Recruiting
  • Community Cancer Institute (CCI)
    Clovis, California 93611-6878, United States
    Recruiting
  • Orange Coast Medical Center
    Fountain Valley, California 92708-6728, United States
    Recruiting
  • Stockton Hematology Oncology Medical Group-2626 N California St
    Stockton, California 95204-6019, United States
    Recruiting
  • Eastern CT Hematology and Oncology Associates
    Norwich, Connecticut 06360-2700, United States
    Recruiting
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010-3017, United States
    Recruiting
  • Cancer and Leukemia Center
    Sterling Heights, Michigan 48314, United States
    Recruiting
  • Renown Health Conrad Breast Center at South Meadows
    Reno, Nevada 89521, United States
    Recruiting
  • Astera Cancer Care East Brunswick
    East Brunswick, New Jersey 08816-4096, United States
    Recruiting
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901-1914, United States
    Recruiting
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109-4495, United States
    Recruiting
  • New York Oncology Hematology (Patroon) - USOR
    Albany, New York 12206-5013, United States
    Recruiting
  • Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2032, 70 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 70 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 21, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Jun 30, 2032
CompletionEst.
Jun 30, 2034
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added
Show 11 added (11 United States)
  • MedStar Washington Hospital Center · Washington D.C., United States
  • Magee Womens Hospital · Pittsburgh, United States
  • Stockton Hematology Oncology Medical Group-2626 N California St · Stockton, United States
  • Renown Health Conrad Breast Center at South Meadows · Reno, United States
  • Astera Cancer Care East Brunswick · East Brunswick, United States
  • New York Oncology Hematology (Patroon) - USOR · Albany, United States
  • Clearview Cancer Institute - Huntsville · Huntsville, United States
  • Community Cancer Institute (CCI) · Clovis, United States
  • Eastern CT Hematology and Oncology Associates · Norwich, United States
  • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
  • New Mexico Oncology Hematology Consultants · Albuquerque, United States
across 3 updates, Oct 9, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    5 sites added
    Show 5 added (5 United States)
    • Clearview Cancer Institute - Huntsville · Huntsville, United States
    • Community Cancer Institute (CCI) · Clovis, United States
    • Eastern CT Hematology and Oncology Associates · Norwich, United States
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
    • New Mexico Oncology Hematology Consultants · Albuquerque, United States
    + 1 other change: verification date
  2. Oct 20, 2026
    4 sites added
    Show 4 added (4 United States)
    • Stockton Hematology Oncology Medical Group-2626 N California St · Stockton, United States
    • Renown Health Conrad Breast Center at South Meadows · Reno, United States
    • Astera Cancer Care East Brunswick · East Brunswick, United States
    • New York Oncology Hematology (Patroon) - USOR · Albany, United States
  3. Oct 9, 2026
    2 sites added
    Show 2 added (2 United States)
    • MedStar Washington Hospital Center · Washington D.C., United States
    • Magee Womens Hospital · Pittsburgh, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07541079
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Aug 25, 2026
Primary completion
Jun 30, 2032 (estimated)
Completion
Jun 30, 2034 (estimated)
Last update
Nov 12, 2026

Study contacts

Reference Study ID Number: GO46747 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion